Viridian Therapeutics, Inc.\DE (VRDN) Long-Term Debt Issuances (2013 - 2023)
Viridian Therapeutics, Inc.\DE's (VRDN) quarterly Long-Term Debt Issuances came in at -$15.0 million in Q4 2023, down 3463.23% year-on-year from $446000.0 in Q4 2022, and down 3463.23% quarter-over-quarter from $446000.0 in Q4 2022.
Viridian Therapeutics, Inc.\DE (VRDN) Long-Term Debt Issuances (2013 - 2023) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Long-Term Debt Issuances history runs 7 years deep, the most recent figure standing at -$15.0 million for Q4 2023.
- On a quarterly basis, Long-Term Debt Issuances fell 3463.23% year-over-year to -$15.0 million in Q4 2023; TTM through Dec 2024 was -$14.6 million, a 2.97% increase from a year earlier, with the FY2025 full-year figure at $28.9 million, changed N/A from the prior year.
- Long-Term Debt Issuances retreated to -$15.0 million in Q4 2023 per VRDN's latest filing, from $446000.0 in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $8.6 million in Q4 2020 and bottomed at -$15.0 million in Q4 2023.
- The 4-year median for Long-Term Debt Issuances is $726000.0 (2020), against an average of -$482000.0.
- Biggest YoY gain for Long-Term Debt Issuances was 3463.23% in 2023; the steepest drop was 3463.23% in 2023.
- Year by year, Long-Term Debt Issuances stood at $1.3 million in 2019, then surged by 542.69% to $8.6 million in 2020, then plunged by 94.79% to $446000.0 in 2022, then plunged by 3463.23% to -$15.0 million in 2023.
- Per Business Quant, the three latest VRDN Long-Term Debt Issuances figures stand at -$15.0 million (Q4 2023), $446000.0 (Q4 2022), and -$446000.0 (Q2 2022).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Viridian Therapeutics, Inc.\DE | 229.55 Mn | 229.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -15.00 Mn |
| Dec 31, 2023 | -15.00 Mn |
| Dec 31, 2022 | 446,000.00 |
| Dec 31, 2022 | 446,000.00 |
| Jun 30, 2022 | -446,000.00 |
| Jun 30, 2022 | -446,000.00 |
| Dec 31, 2020 | 8.57 Mn |
| Dec 31, 2020 | 8.57 Mn |
| Jun 30, 2020 | 726,000.00 |
| Jun 30, 2020 | 726,000.00 |
| Mar 31, 2020 | 1.00 Mn |
| Mar 31, 2020 | 1.00 Mn |
| Sep 30, 2019 | 1.33 Mn |
| Sep 30, 2019 | 1.33 Mn |
| Dec 31, 2017 | 3.17 Mn |
| Dec 31, 2017 | 3.17 Mn |
| Sep 30, 2017 | 500,000.00 |
| Sep 30, 2017 | 500,000.00 |
| Jun 30, 2017 | 500,000.00 |
| Jun 30, 2017 | 500,000.00 |